SCHEMBL19536005

SCHEMBL19536005

Nc1nc2c(ncn2[C@@H]2O[C@H](CO)C(O)[C@]2(O)C#CCF)c(=S)[nH]1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 6/20 0.45
▸ ADA P00813 1/20 0.40
▸ LMNA P02545 1/20 0.37
▸ NT5E P21589 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ ADORA3 P0DMS8 3/20 0.37
▸ ADORA1 P30542 3/20 0.37
▸ ADORA2B P29275 3/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ PDE2A O00408 1/20 0.36
▸ ADRA1A P35348 1/20 0.36
▸ PDE4D Q08499 1/20 0.36
▸ PDE3A Q14432 1/20 0.36
▸ SLC29A1 Q99808 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19535505 0.91 ADORA2A (0.46) ADORA2AADALMNANT5EHIF1A
SCHEMBL19536694 0.90 ADORA2A (0.42) ADORA2AADALMNANT5EHIF1A
SCHEMBL19537284 0.90 ADORA2A (0.42) ADORA2AADALMNANT5EHIF1A
SCHEMBL19535918 0.90 ADORA2A (0.48) ADORA2AADALMNAADORA3ADORA1
SCHEMBL21006854 0.90 ADORA2A (0.48) ADORA2AADALMNAADORA3ADORA1
SCHEMBL19536589 0.90 ADORA2A (0.48) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL19536548 0.90 ADORA2A (0.48) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL19537249 0.89 ADORA2A (0.44) ADORA2AADALMNANT5EHIF1A
SCHEMBL19535988 0.89 ADORA3 (0.46) ADORA2ANT5EADORA3PDE3A
SCHEMBL19536425 0.88 ADORA2A (0.47) ADORA2AADALMNANT5EHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017189978-A1 ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2017-11-02 — — WO disclosed
Send feedback